{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:20:28Z","timestamp":1790014828589,"version":"4.0.1"},"reference-count":31,"publisher":"Korean Cancer Association","issue":"4","license":[{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp & Dohme Corp.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["e-crt.org"],"crossmark-restriction":true},"short-container-title":["Cancer Res Treat"],"published-print":{"date-parts":[[2024,10,15]]},"abstract":"<jats:p>Purpose Optimal treatment for stage IIIA\/N2 non\u2013small cell lung cancer (NSCLC) is controversial. We aimed to assess the efficacy and safety of adjuvant pembrolizumab for stage IIIA\/N2 NSCLC completely resected after neoadjuvant concurrent chemoradiation therapy (CCRT).Materials and Methods In this open-label, single-center, single-arm phase 2 trial, patients with stage IIIA\/N2 NSCLC received adjuvant pembrolizumab for up to 2 years after complete resection following neoadjuvant CCRT. The primary endpoint was disease-free survival (DFS). Secondary endpoints included overall survival (OS) and safety. As an exploratory biomarker analysis, we evaluated the proliferative response of blood CD39+PD-1+CD8+ T cells using fold changes in the percentage of proliferating Ki-67+ cells from days 1 to 7 of cycle 1 (Ki-67D7\/D1).Results Between October 2017 and October 2018, 37 patients were enrolled. Twelve (32%) and three (8%) patients harbored EGFR and ALK alterations, respectively. Of 34 patients with programmed cell death ligand 1 assessment, 21 (62%), nine (26%), and four (12%) had a tumor proportion score of &lt; 1%, 1%-50%, and \u2265 50%, respectively. The median follow-up was 71 months. The median DFS was 22.4 months in the overall population, with a 5-year DFS rate of 29%. The OS rate was 86% at 2 years and 76% at 5 years. Patients with tumor recurrence within 6 months had a significantly lower Ki-67D7\/D1 among CD39+PD-1+CD8+ T cells than those without (p=0.036). No new safety signals were identified.Conclusion Adjuvant pembrolizumab may offer durable disease control in a subset of stage IIIA\/N2 NSCLC patients after neoadjuvant CCRT and surgery.<\/jats:p>","DOI":"10.4143\/crt.2024.084","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T05:11:14Z","timestamp":1714453874000},"page":"1084-1095","update-policy":"https:\/\/doi.org\/10.4143\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Adjuvant Pembrolizumab in Patients with Stage IIIA\/N2 Non\u2013Small Cell Lung Cancer Completely Resected after Neoadjuvant Concurrent Chemoradiation: A Prospective, Open-Label, Single-Arm, Phase 2 Trial"],"prefix":"10.4143","volume":"56","author":[{"given":"Junghoon","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sehhoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eui-Cheol","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Ae","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Ho","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Mu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Soo","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Seok","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhingook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keunchil","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Mog","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong Kwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Myoung","family":"Noh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Chan","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongryull","family":"Pyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2954","reference":[{"key":"ref1","volume-title":"","author":"Amin","year":"2017"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(10)60059-1"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(13)62159-5"},{"key":"ref4","first-page":"39","volume-title":"The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer","author":"Goldstraw","year":"2016"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-018-1313-x"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(09)60737-6"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2016.03.016"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02528"},{"key":"ref9","first-page":"1973","volume-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","author":"Forde","year":"2022"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)02098-5"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00518-6"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30453-8"},{"key":"ref13","first-page":"504","volume-title":"Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer","author":"Provencio","year":"2023"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2302983"},{"key":"ref15","first-page":"1672","volume-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","author":"Heymach","year":"2023"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01261"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz167"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26689"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)60294-x"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/jto.0b013e31824c7d92"},{"key":"ref21","first-page":"172","volume-title":"Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer","author":"Scagliotti","year":"2012"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2002.08.092"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2003.11.040"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(08)70156-6"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00383-1"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-1449"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1705327114"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21619-0"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.12.001"},{"key":"ref30","first-page":"137","volume-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","author":"Tsuboi","year":"2023"},{"key":"ref31","first-page":"1241","volume-title":"Phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR- or ALK-mutated non-small-cell lung cancer (ATTLAS, KCSG-LU19-04)","author":"Park","year":"2024"}],"container-title":["Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2024-084.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2024.084","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2024-084.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T23:44:43Z","timestamp":1728863083000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2024.084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"URL":"https:\/\/doi.org\/10.4143\/crt.2024.084","relation":{},"ISSN":["1598-2998","2005-9256"],"issn-type":[{"value":"1598-2998","type":"print"},{"value":"2005-9256","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,15]]},"assertion":[{"value":"2024-01-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-30","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-15","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}